• Users Online: 391
  • Print this page
  • Email this page
CASE REPORT
Year : 2022  |  Volume : 9  |  Issue : 1  |  Page : 26-28

Pembrolizumab as a bridge to autologous stem cell transplantation in refractory gray zone lymphoma


1 Division of Hematology, Department of Medicine, Taipei Veterans General Hospital; Faculty of Medicine, National Yang Ming Chiao Tung University; Division of Medical Oncology, Department of Oncology, Center for Immuno-Oncology, Taipei Veterans General Hospital; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
2 Division of Hematology, Department of Medicine, Taipei Veterans General Hospital; Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
3 Faculty of Medicine, National Yang Ming Chiao Tung University; Division of Medical Oncology, Department of Oncology, Center for Immuno-Oncology, Taipei Veterans General Hospital; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

Correspondence Address:
Dr. San-Chi Chen
Division of Medical Oncology, Department of Oncology, Center for Immuno-oncology, Taipei Veterans General Hospital, Taipei, Taiwan, No. 201, Sec. 2, Shipai Road, Taipei 11217
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JCRP.JCRP_34_21

Rights and Permissions

Gray zone lymphoma (GZL), a rare type of B-cell lymphoma (BCL), has features between diffuse large BCL and classical Hodgkin lymphoma (cHL) and an unfavorable outcome. The expression of PD-L1, encoded by chromosome 9p24.1, has been positively correlated with the copy number alteration of 9p24.1, and it has been associated with a high response rate to anti-PD-1 treatment in cHL and primary mediastinal large BCL (PMBCL). GZL shares similar genomic alterations with cHL and PMBCL, and thus, it may also respond well to anti-PD-1 treatment. However, little is known about the efficacy of anti-PD-1 treatment and the predictive role of PD-L1 expression in GZL. Here, we present a case of GZL refractory to first-line chemotherapy. The patient had a high expression of PD-L1 and was successfully treated with pembrolizumab as a salvage treatment, followed by autologous stem cell transplantation (ASCT) in January 2018. The patient still had a complete metabolic response 42 months after ASCT.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1066    
    Printed14    
    Emailed0    
    PDF Downloaded112    
    Comments [Add]    

Recommend this journal